Inclusion criteria
tumors, Histologically-confirmed squamous cell carcinoma, Cancer
ESOPHAGEAL CANCER, CAVITY, ONCOLOGY, TUMORS, CANCER

The patient volunteers agreed to participate in the study, signed a consent form, exhibited good compliance, observed the follow-up procedures, and were willing and able to follow the protocol during the study.Histologically-confirmed squamous cell carcinoma; tumors of the esophagus are located in the thoracic cavity.The patients had not received systemic or local treatment for esophageal cancer.Pretreatment staging was cT1b-3N1-3M0 or T3N0M0, American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) 8th edition.Male or female, aged ≥ 18 and ≤ 75 years.The Eastern Cooperative Oncology Group (ECOG) performance status (PS) score is 0–1.R0 resection is expected.Adequate cardiac function: all patients were expected to undergo electrocardiogram (ECG), and those with a cardiac history or ECG abnormality were expected to undergo echocardiography with left ventricular ejection fraction > 50%.Adequate respiratory function with forced expiratory volume in 1 s (FEV1) ≥ 1.2 L, FEV1% ≥ 50%, and lung diffusing capacity for carbon monoxide (DLCO) ≥ 50% shown in pulmonary function tests.Adequate bone marrow function (white blood cells > 4 × 10Adequate liver function (total bilirubin < 1.5× ULN, AST and ALT < 2.5× ULN).Adequate renal function (glomerular filtration rate (GFR) > 60 mL/min; serum creatinine (SCr) ≤ 120 µmol/L].Fertile female subjects were e required to have a negative serum or urine pregnancy test no later than 72 h before starting the study drug administration, and to use effective contraception (such as an IUD, contraceptive pill, or condom) during the trial period and for at least 3 months after the last dose; male subjects whose partners were women of reproductive age; were instructed to use effective contraception should be used during the trial period and within 3 months after the last dose.